8-K filed May 11, 2022, 7:59 PM ET ticker IMDX CIK 0001642380

earnings confidence high sentiment negative materiality 0.65

Oncocyte Q1 revenue $1.4M, net loss widens; CFO and Chairman transitions announced

Insight Molecular Diagnostics Inc.

2023-Q1 EPS reported -$0.11 revenue$1,424,000

Q1 2022 total revenue $1.4M vs $1.1M YoY; DetermaRx revenue $1.0M.
Net loss $10.3M ($0.11 per share) vs net loss $3.9M ($0.05) a year ago.
Cash, equivalents & marketable securities $22.7M as of March 31, 2022.
Chairman Cavan Redmond not standing for reelection; Andrew Arno appointed Chairman effective May 6.
CFO Mitchell Levine to transition to Corporate Development Officer; Anish John named Interim CFO.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Mitchell Levine

Chief Financial Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-06-01
Successor: Anish John
Filed: May 11, 2022, 7:59 PM ET

Mitchell Levine, our Chief Financial Officer since 2017, will no longer serve in that capacity as of June 1, 2022.

Role change

Cavan Redmond

Chairman of the Board

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-05-06
Successor: Andrew Arno
Filed: May 11, 2022, 7:59 PM ET

Mr. Redmond has stepped down as Chairman of the Board, and that the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.

Appointed

Andrew Arno

Chairman of the Board

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-05-06
Filed: May 11, 2022, 7:59 PM ET

the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.

Appointed (interim)

Anish John

Senior Vice President, Finance, and Interim Chief Financial Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-06-01
Filed: May 11, 2022, 7:59 PM ET

Anish John, our Vice President, Operations – Transplant, has been appointed Senior Vice President, Finance, and Interim Chief Financial Officer effective June 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mitchell Levine changed role as Chief Financial Officer at Insight Molecular Diagnostics Inc..

Action: will no longer serve
Role: Chief Financial Officer

Exact text from the filing

Mitchell Levine, our Chief Financial Officer since 2017, will no longer serve in that capacity as of June 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Cavan Redmond changed role as Chairman of the Board at Insight Molecular Diagnostics Inc..

Action: stepped down
Role: Chairman of the Board

Exact text from the filing

Mr. Redmond has stepped down as Chairman of the Board, and that the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Andrew Arno was appointed as Chairman of the Board at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Anish John was appointed as Senior Vice President, Finance, and Interim Chief Financial Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Senior Vice President, Finance, and Interim Chief Financial Officer

Exact text from the filing

Anish John, our Vice President, Operations – Transplant, has been appointed Senior Vice President, Finance, and Interim Chief Financial Officer effective June 1, 2022.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-012856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.